Biocon Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The Board of Directors has recommended a final dividend of 10% (Rs. 0.50 per share). Key strategic developments include the full integration of Biocon Biologics Limited (BBL) as a wholly-owned subsidiary and the approval of a Long-Term Incentive Plan for employees. Additionally, the company has appointed new statutory auditors and expanded its board of directors.
Financial Highlights
For the financial year ended March 31, 2026, Biocon reported standalone revenue from operations of Rs. 23,464 million. On a consolidated basis, the company delivered a robust performance, with consolidated revenue from operations reaching Rs. 1,31,453 million for the same period. The Board has recommended a final dividend of Rs. 0.50 per equity share (face value of Rs. 5), subject to shareholder approval, with a record date set for July 3, 2026.
Strategic Integration of Biocon Biologics
A significant highlight of the announcement is the strategic move to fully integrate Biocon Biologics Limited (BBL) as a wholly-owned subsidiary of the Company. This process involves the acquisition of remaining equity shares from employees and shareholders through a preferential issue of 87,92,317 equity shares of Biocon, valued at an issue price of Rs. 376.16 per share. This integration is designed to simplify the corporate structure, enable a unified capital allocation strategy, and capture operational synergies from the combined biosimilars and GLP-1 portfolios.
Leadership and Governance Changes
The company announced several key leadership updates. Dr. Anuj Goel (Chief Development Officer) and Mr. Susheel Umesh (Chief Commercial Officer – Emerging Markets) have been designated as Senior Management Personnel. In governance, the Board has recommended the appointment of M/s. S. R. Batliboi & Associates LLP as the new Statutory Auditors for a five-year term starting from the 48th Annual General Meeting (AGM).
Board Reconstitution
To support its unified global strategy, the Board has approved the appointment of several new Independent Directors effective August 1, 2026, including Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai. Additionally, Mr. Thomas Jason Roberts has been recommended as a Non-Executive Non-Independent Director. The 48th AGM is scheduled for August 6, 2026, via video conferencing.
Source: BSE
